An increased risk of dying was observed in people treated with<unk>  as compared to other antibiotics in a separate clinical trial. Most of the deaths occurred in people hospitalized with other kinds of severe bacterial infections (pneumonia, sepsis, or infection in the blood). The cause of death was not clear.<unk>  may cause serious and life-threatening allergic reactions, severe diarrhea caused by C. difficile and seizures. Labeling for<unk>  includes a warning regarding the higher all-cause mortality rate observed in<unk> -treated people compared to those treated with other antibiotics in a trial in critically ill people with multidrug-resistant Gram-negative bacterial infections. The cause of the increase in mortality has not been established. Some of the deaths were a result of worsening or complications of infection, or underlying co-morbidities. The higher all-cause mortality rate was observed in people treated for hospital-acquired/ventilator-associated pneumonia (i.e.nosocomial pneumonia), bloodstream infections, or sepsis. The safety and efficacy of<unk>  has not been established for the treatment of these types of infections.
Cefiderocol
Sucralfate
Loperamide
Cefoperazone
Ornidazole
Cimetidine
Secnidazole
Lactulose